United States: Fresenius Kabi's Actemra® Biosimilar Tyenne® (Tocilizumab-aazg) Approved In The U.S. - Venable LLP

United States: Fresenius Kabi's Actemra® Biosimilar Tyenne® (Tocilizumab-aazg) Approved In The U.S. - Venable LLP

Mondaq

Published

On March 5, 2024, the FDA approved Fresenius Kabi's Tyenne® (tocilizumab-aazg) as a biosimilar of Chugai, Genentech and Hoffman-La Roche's Actemra® (tocilizumab).

Full Article